Sequence Information

    • DRAMP ID

    • DRAMP28983

    • Name

    • PL-5

    • Sequence

    • kkllfklkfkk

    • Description

    • This product is a national category 1 anti-infective innovation category in China, and has obtained PCT US and Chinese invention patent authorizations. Suitable for skin and wound infections, especially for stubborn infectious diseases caused by drug-resistant bacteria, against traditional antibiotics, "super bacteria" Pseudomonas aeruginosa, and methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Acinetobacter baumannii containing NDM-1 gene have very strong bactericidal advantages. Its preparation antimicrobial peptide PL-5 spray is the first antimicrobial peptide variety to enter clinical research in my country, and this product has also been supported by the National Health and Family Planning Commission’s 12th and 13th Five-Year "Major New Drug Development" projects. Phase I clinical research has been completed, and Phase II clinical research is currently underway.

    • Activity

    • Antibacterial

    • Target Organism

      • Gram-positive bacteria:
        Staphylococcus aureus ATCC25923(MIC = 0.75μg/mL), Staphylococcus epidermidis C621(MIC = 0.9 μg/mL), Bacillus subtilis ATCC49619(MIC= 1 μg/mL);
      • Gram-negative bacteria:
        Escherichia coli ATCC25922 (MIC = 0.75μg/mL), Pseudomonas aeruginosa ATCC27853(MIC = 2.8 μg/mL)

    • Reference

      • Novel Antibacterial Peptide And Application Thereof

Clinical Information

    • Medical use

    • Skin wound infection

    • Company

    • Changchun ProteLight Pharmaceutical & Biotechnology Co.

    • Stage of Development

    • Phase IIIb

    • Comments

    • No more comments

    • Clinical Trials

    • ChiCTR2300071255
    • ChiCTR2100047202
    • ChiCTR2000033334